Meeting
2022 ASCO Annual Meeting
Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
Authors
Noura J. Choudhury
Memorial Sloan Kettering Cancer Center, New York, NY
Noura J. Choudhury , Antonio Marra , Soo-Ryum Yang , Christina J. Falcon , Glenn Heller , Mark G. Kris , Jorge S. Reis-Filho , Gregory J. Riely , Helena Alexandra Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9100)
DOI
10.1200/JCO.2022.40.16_suppl.9100
Abstract #
9100
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).
First Author: Kabir Mody
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss
Poster
2020 ASCO Virtual Scientific Program
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
First Author: Matthew P. Goetz